Truist Financial Corp Eagle Pharmaceuticals, Inc. Transaction History

Truist Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $565,372 - $702,089	-12,339 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$43.79 - $55.78 $1,269 - $1,617	-29 Reduced 0.23%	12,339 $688,000
Q2 2021 Aug 16, 2021	SELL	$36.86 - $44.5 $442 - $534	-12 Reduced 0.1%	12,368 $529,000
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $967 - $1,223	24 Added 0.19%	12,380 $517,000
Q4 2020 Nov 19, 2021	SELL	$41.72 - $51.34 $31,164 - $38,350	-747 Reduced 5.7%	12,356 $575,000
Q4 2020 Feb 18, 2021	SELL	$41.72 - $51.34 $223,368 - $274,874	-5,354 Reduced 29.01%	13,103 $610,000
Q3 2020 Nov 13, 2020	BUY	$37.02 - $51.28 $2,073 - $2,871	56 Added 0.3%	18,457 $784,000
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $345 - $440	8 Added 0.04%	18,401 $883,000
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $549 - $961	16 Added 0.09%	18,393 $846,000
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $998,238 - $1.18 Million	18,377 New	18,377 $1.1 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.